Sun-Novo(SH:688621) Zheng Quan Zhi Xing·2025-05-12 12:25Core Viewpoint - Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd. plans to deregister its subsidiary Nanjing Nuohexin Pharmaceutical Technology Co., Ltd. to optimize internal management and reduce operational costs [1][2] Group 1: Company Overview - The company is proposing to deregister its controlling subsidiary Nanjing Nuohexin, which is considered a related transaction but does not constitute a major asset restructuring [1][2] - Zhao Lingyang, who held various positions in the company from January 2019 to September 2024 and owns 18% of Nuohexin, is identified as a related party [2][3] Group 2: Financial Information - Nuohexin's total assets as of December 31, 2024, were approximately 10.14 million yuan, up from about 8.74 million yuan in 2023, indicating a growth of approximately 15.98% [4] - The total liabilities of Nuohexin increased from approximately 872,784.84 yuan in 2023 to about 9.19 million yuan in 2024, reflecting a significant rise [4] - Nuohexin reported a total revenue of approximately 7.60 million yuan in 2024, with a net loss of about 6.92 million yuan, compared to a net loss of approximately 3.23 million yuan in 2023 [5] Group 3: Reasons for Deregistration - The decision to deregister Nuohexin is based on the company's development plan and the operational status of the subsidiary, aiming to streamline management and enhance operational efficiency [2][5] - After deregistration, the core business and employees of Nuohexin will be managed by its controlling shareholder, ensuring a smooth transition and protection of employee rights [5] Group 4: Impact of Deregistration - The proposed deregistration is not expected to have a significant impact on the overall business development and profitability of the company, although it will change the scope of the consolidated financial statements [5]